What is the equity of Zura Bio this year?
Zura Bio has equity of 59.33 M USD this year.
In 2024, Zura Bio's equity was 59.33 M USD, a -55.62% increase from the 133.7 M USD equity in the previous year.
Zura Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Zura Bio's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Zura Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Zura Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Zura Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Zura Bio has equity of 59.33 M USD this year.
The equity of Zura Bio has increased/decreased by -55.62% decreased compared to the previous year.
A high equity is advantageous for investors of Zura Bio as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Zura Bio, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Zura Bio can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Zura Bio can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Zura Bio include profits, dividend payments, capital increases, and acquisitions.
The equity of Zura Bio is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Zura Bio can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Zura Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zura Bio is expected to pay a dividend of 0 USD.
The current dividend yield of Zura Bio is .
Zura Bio pays a quarterly dividend. This is distributed in the months of .
Zura Bio paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Zura Bio is assigned to the 'Health' sector.
To receive the latest dividend of Zura Bio from 6/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/9/2024.
The last dividend was paid out on 6/9/2024.
In the year 2023, Zura Bio distributed 0 USD as dividends.
The dividends of Zura Bio are distributed in USD.
Our stock analysis for Zura Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zura Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.